Diagnostic Criteria in Cardiac Sarcoidosis
Evaluation of Diagnostic Criteria in Cardiac Sarcoidosis - an Observational Study
Heart Center Leipzig - University Hospital
100 participants
May 1, 2023
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to evaluate the accuracy of the current diagnostic criteria of cardiac sarcoidosis.
Eligibility
Inclusion Criteria12
- patients with suspected CS due to the following presentations:
- age < 65 years and new higher degree AV block, causative coronary artery disease excluded
- age < 65 years and new ventricular tachycardia, causative coronary artery disease excluded
- age < 65 years and ventricular tachycardia, causative coronary artery disease excluded
- extracardiac sarcoidosis and cardiac involvement suggested (palpitations, abnormal ECG, abnormal echocardiography)
- To diagnose CS one of the following diagnostic tools will be used:
- A) World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG)
- B) Heart Rhythm Society expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis
- C) Japanese Society of Nuclear Cardiology (JSNC)
- Patients whit histological confirmation from myocardial tissue fullfil will be defined as proven CS. (Group 1)
- Patients with clinical and imaging findings highly suggesting CS, but without histological confirmation from myocardial biopsy will be defined as probable CS (Group 2)
- Patients who do not fullfil the criteria or exhibiting findings suggesting an alternative, more likely diagnosis, will be considered as unlikely CS (Group 3)
Exclusion Criteria4
- unable or unwilling to provide informed consent
- patients who are pregnant or lactating
- noncompliant patients refusing the recommended therapy
- age < 18 years
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ECG - 12 leads ECG Echo: transthoracic echocardiography laboratory tests: full blood count, electrolytes, creatinine, high sensitive cardiac troponin T, angiontesin converting enzyme, soluble interleukin-2 receptor, cardiac magnetic resonance imaging: 1.5 Tesla scanner, Conventional cine imaging and late gadolinium enhancement imaging PET-CT: 18F-fluorodeoxyglucose (FDG)- positron emission tomograph Biopsy: cardiac biopsy = endomyocardial biopsy, left and right ventricle, at least 5 specimens in formaldehyd and 3 specimens for testing of infectious agents Biopsy: extracardiac biopsy, as accessible according to imaging
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04737317